No Data
Komodo Health Introduces the First Integrated Patient Insurance Dataset to Enhance Patient-Level Insights for Life Sciences
Komodo Sets a New Industry Standard for Applying Real-World Data and Analytics to More Accurately Understand Patient Insurance Status at Both Regional and National LevelsSAN FRANCISCO--(BUSINESS WIRE)
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $100
H.C. Wainwright analyst Ram Selvaraju maintains $MoonLake Immunotherapeutics(MLTX.US)$ with a buy rating, and maintains the target price at $100.According to TipRanks data, the analyst has a success r
BTIG Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $71
BTIG analyst Julian Harrison maintains $MoonLake Immunotherapeutics(MLTX.US)$ with a buy rating, and maintains the target price at $71.According to TipRanks data, the analyst has a success rate of 49.
Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $66
Needham analyst Serge Belanger maintains $MoonLake Immunotherapeutics(MLTX.US)$ with a buy rating, and maintains the target price at $66.According to TipRanks data, the analyst has a success rate of 4
MoonLake Immunotherap Price Target Maintained With a $66.00/Share by Needham
MoonLake Immunotherap Price Target Maintained With a $66.00/Share by Needham
Express News | Needham Reiterates Buy on MoonLake, Maintains $66 Price Target